Fluctuations in Symptoms in Human Immunodeficiency Virus-Infected Children: The First 10 Years of Life
- 1 July 2001
- journal article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 108 (1) , 116-122
- https://doi.org/10.1542/peds.108.1.116
Abstract
To describe patterns of clinical and immunologic progression in children who are vertically infected with the human immunodeficiency virus. Children who were born to mothers who were infected with the human immunodeficiency virus in 11 European centers were enrolled at birth in a prospective study and followed according to a standard protocol. At each visit, a clinical and immunologic class was allocated according to guidelines of the Centers for Disease Control and Prevention (CDC). Progression to serious disease and death was assessed, allowing for available and actual antiretroviral therapy (ART). CDC class at each visit was assessed cross-sectionally. More than 15% of infected children will have progressed to category C or death by age 1 year and nearly 50% by 10 years. Just under 20% of children will have evidence of severe immunodeficiency by age 1 and 75% by 10 years. In general, immune status poorly reflected clinical condition. Children who were born after 1994, when the recommendation of earlier initiation of more active therapy was introduced, were significantly less likely to progress than those who were born when treatment was not widely available or was largely confined to zidovudine monotherapy. Estimated progression to CDC class C or death initially was faster in untreated than in treated children, but by 10 years estimated cumulative progression was similar in both groups. Treatment started before class C disease was associated with significantly slower progression. Cross-sectional analysis showed that children largely are symptom-free throughout their lives. After 4 years of age, fewer than 25% of infected children had symptoms at any one time, irrespective of ART received. Vertically infected children are without serious symptoms or signs for most of the time. The prognosis has improved with more widespread availability and use of combination ART. These findings have implications for health, education, and other support-service provision.Keywords
This publication has 13 references indexed in Scilit:
- Reduction in Mortality With Availability of Antiretroviral Therapy for Children With Perinatal HIV-1 InfectionJAMA, 2000
- Variable use of therapeutic interventions for children with human immunodeficiency virus type 1 infection in Europe.European Journal of Pediatrics, 2000
- Rapid disease progression in HIV-1 perinatally infected children born to mothers receiving zidovudine monotherapy during pregnancyAIDS, 1999
- Genotypic and phenotypic resistance under zidovudine and lamivudine therapy in human immunodeficiency virus-infected childrenEuropean Journal of Pediatrics, 1999
- Association of Human Immunodeficiency Virus (HIV) Load Early in Life with Disease Progression among HIV-Infected InfantsThe Journal of Infectious Diseases, 1998
- Morbidity and Mortality in European Children Vertically Infected by HIV-1JAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine TreatmentNew England Journal of Medicine, 1994
- CD4 T cell count as predictor of Pneumocystis carinii pneumonia in children born to mothers infected with HIVBMJ, 1994
- Features of children perinatally infected with HIV-1 surviving longer than 5 years: Italian Register for HIV Infection in ChildrenThe Lancet, 1994
- Prophylactic Intravenous Immunoglobulin in HIV-Infected Children With CD4+ Counts of 0.20×109/L or MoreJAMA, 1992